Cytokine modifiers: Pipe dream or reality?

Chest

Volumn 113, Issue 3 SUPPL., 1998, Pages 224S-227S

  Abraham, Edward ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY; P55 TUMOR NECROSIS FACTOR RECEPTOR FUSION PROTEIN; P75 TUMOR NECROSIS FACTOR RECEPTOR FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG SCREENING; HUMAN; INTENSIVE CARE; MORTALITY; MULTIPLE ORGAN FAILURE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEPTIC SHOCK; TREATMENT OUTCOME;

EID: 0031894547     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (10)

1. Fisher CJ, Slotman GJ, Opal SM, et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 1994; 22:12-21
2. Fisher CJ, Dhainaut J-FA, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA 1994; 271:1836-43
3. Opal SM, Fisher CJ, Pribble JP, et al. The confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med (in press)
4. Abraham E, Wunderink R, Silverman H, et al. Monoclonal antibody to human tumor necrosis factor alpha (TNFα MAb): efficacy and safety in patients with the sepsis syndrome. JAMA 1995; 273:934-41
5. Cohen J, Carlet J, for the INTERSEPT Study Group. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis. Crit Care Med 1996; 24: 1431-40
6. Abraham E, and the NORASEPT II Study Group. Effect of murine monoclonal antibody to human tumor necrosis factor (Bay X 1351) in patients with septic shock [abstract]. Chest 1997;112:47S-48S
7. Reinhart K, Wiegand-Lohnert C, Grimminger F, et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996; 24:733-42
8. Fisher CJ, Agosti JM, Opal SM, et al. Treatment of patients with septic shock with tumor necrosis receptor Fc fusion protein. N Engl J Med 1996; 334:1697-1702
9. Abraham E. Status report of soluble receptors in the treatment of septic shock [abstract]. Presented at IBC Sixth Annual International Symposium on Sepsis, Boston, June 25, 1996
10. Evans TJ, Moves D, Carpenter A, et al. Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J Exp Med 1994; 180:2173-79